The optimal management of renal replacement therapy (RRT) 
Introduction
Acute renal failure (ARF) is an abrupt loss of renal function resulting in the failure of the kidneys to excrete urea and other nitrogenous waste products. Despite substantial advances in our understanding of the pathogenesis of ARF, clinical advances in treatment have been limited, and morbidity and mortality remain high. Although multiple pharmacologic interventions have shown promise in animal models, no agents have proven to be effective in clinical practice 11, 21 . As a result, the management of ARF is primarily supportive, with renal replacement therapy (RRT) serving as the mainstay of treatment in patients with severe renal failure. Despite more than a half-century of experience, many fundamental issues regarding the management of RRT in ARF remain to be resolved, including the indications for and timing of initiation of therapy, the selection of modality of RRT, and the optimal dosing of therapy [3, 4] .
In patients with ARF, RRT is commonly initiated either to treat overt manifestations of renal failure (i.e., urernic symptoms, volume overload, aRenal Section, VA Pittsburgh Healthcare System and Department of Medicine, University of Pittsburgh School of hyperkalemia and metabolic acidosis) or, in the absence of overt symptoms, in response to progressive azotemia 151. An increasing number of modalities of RRT are used in clinical practice. Iintermittent hemodialysis is the most commonly prescribed form of renal support, usually provided on a three to four times per week schedule. Other modalities, such as the continuous renal replacement therapies (CRRT) and sustained low efficiency dialysis (SLED) have gained increasing acceptance in the management of hemodynamically unstable patients. Although several recent clinical studies have suggested that more intensive renal support may improve survival , these data have not been widely accepted in clinical practice in the USA 14,91. In addition, these studies evaluated individual modalities of therapy in isolation rather than evaluating strategies of care that parallel clinical practice.
In light of the lack of consensus regarding best practice of renal support in ARF, the VA/NIH Acute Renal Failure Trial Network Study (ATN Study) was conceived to address the question of whether there is a benefit to delivering more intensive RRT in critically ill patients. The ATN Study is a prospective, randomized trial involving protocol-driven treatment strategies of titrated therapies. it compares a strategy of intensive renal support to more conventionally utilized (conveintional) management of RRT, ultilizing multiple modalities of RRT within each treatment arm. The primary study hypothesis is that intensive renal support will decrease mortality in critically ill patients with ARF as compared to more conventional management of RR 1. Secondary hypotheses are that intensive renal support will shorten the duration of ARF, will decrease the incidence and duration of nonrenal complications, and will be cost-effective. The Baseline data collection includes demographic data, history and physical examination, medications, comprehensive laboratory assessment, hemodynamic assessment and assessment of nutritional management. Chronic comorbidities and acuity of illness are assessed using standard assessment scores [11-141. Detailed data on renal replacement therapy are collected on a daily basis through to day 28 A separate informed consent is utilized for the DNA repository. For subjects lacking decisionmaking capacity, informed consent to obtain the DNA sample is obtained from the legally identified surrogate decision-maker; however, the DNA sample is not logged into the DNA repository until the subject regains decision-making capacity and provides consent. lf the subject does not provide consent, the sample is destroyed. If the subject expires prior to regaining decision-making capacity, further consent is not required and the specimen is logged into the DNA repository.
Observational cohort
In order to ascertain the relationshlip between the study treatment arms aind the standard of care for managemient of RRT outside of the research context, observational data are being collected on the management of RRT in patients excluded from the primary study as the result of inability to obtain informed consent within the eligibility window. Demographic data collected include age, gender, race, and etiology of ARE Clinical data include the timing of initiation of RRT' the indications for RR'I; and the blood urea nitrogen concentration and SOFA cardiovascular score on the day RRT was initiated. Detailed treatment data, analogous to that collected on subjects in the intervention trial, are collected for each RRT 
Interim monitoring and analyses
Interim monitoring will focus on both the efficacy and safety of the study. Trial safety is being monitored after 60-day follow-up of each 200-subject block, or every 6 months, whichever comes first. At these interim safety analyses, a one-sided significance level of 0.00005 is used as the criterion for assessment of efficacy, even though no assessment of efficacy is intended. The inflated type-1 error will be ignored.
Planned interim efficacy analyses will be performed when 600 and 900 subjects have been enrolled and followed for 60days. For the interim efficacy analyses, a wide boundary such as that proposed by Haybittle and Peto will be used [23] . The one-sided significance level in favor of intensive treatment for the interim analyses will be 0.0005. Feasibility monitoring will be performed at the two interim efficacy analyses based on the conditional power for the trend.
Final analysis
All analyses will be performed based on intentionto-treat. Analysis of the primary endpoint, 60-day all-cause mortality, will be performiled using a conditional logistic regression for a binary endpoint. Two analyses will be carried out: 1) treatment adjusted for the study design (cardiovascular SOFA score, oliguric status and site); and 2) treatment adjusted for the study design and for a set of prespecified explanatory variables. Treatment by explanatory variable interactions will be examined in exploratory analyses. These explanatory variables include gender, age at randomization, primary diagnosis, Charlson Comorbidity score, etiology of acute renal failure, presence of oliguria, acuity of illness scores, use of mechanical ventilation, and presence of sepsis. Prespecified subgroup analyses will be performed for oliguric status, cardiovascular SOFA score, and gender.
A significance level of 0.05 (two-sided) will be used for all secondary outcomes. All-cause hospital mortality by day 60 will be analyzed in a inanner similar to the primary outcome. One-year all-cause mortality will be analyzed using Kaplan-Meier survival curves, adjusted for censoring due to loss to follow-up. Treatment group comparisons will be based on the stratified log-rank test. The Cox proportional hazards model will be used to test the effect of treatment adjusted for the study design and for the prespecified set of covariates. A similar analysis will be conducted for 60-day all-cause mortality. Recovery of renal function by 28 days is a three-level ordinal measuremnent: none, partial, and conmplete recovery. A conditional odds ratio model will be used to investigate the effect of treatment on recovery of renal function.
Economic analysis
This study will include cost-outcome and costeffectiveness analyses. Ihe cost-outcome analysis will compare the difference in total costs between the intensive and conventional treatment arms to the difference in the primnary outcome, 60-day mortality. The cost-effectiveness analysis will compare the change in quality-adjusted life years (QALYs) between the arms to the difference in costs. Economic data will include vital status, health care utilization, costs, and preferences (utilities). Vital status and health care utilization will come from study forms, hospital data systems, and public records. Costs will be extracted from providers' electronic data systems. Actual cost estimates will be available from VA sites; non-VA sites will provide patient charges that will then be adjusted using facility-specific Medicare cost-to-charge ratios. The Health Utilities Indexc) (HU1) will be administered at 60days anid 12 months after randomization to measure utility. HUI scores will be converted to utility scores (range 0.0-1.0) based on surveys of general populations [24] . A societal viewpoint will be adopted for the economic analyses. 1261 did not confirm this benefit, however, this study was underpowered and its observed 28-day patient survival of 72.6% suggests inclusion of a less critically ill study population. Schiffl et al. [7] compared daily hemodialysis to every-other-day hemodialysis in 160 subjects. Although there was a reduction in mortality from 46% with every-otherday hemodialysis to 28% in the daily treatment group, several methodological concerns have been raised about this study [4] . Subjects were assigned to therapy on an alternating basis, rather than by raindom assignment, although their baseline characteristics were comparable. More importantly, the delivered dose of dialysis was substantially lower than the target spKt/V,Lrea of 1.2, resulting in an elevated time-averaged blood urea nitrogen concentratioIn (104 + 18mg/dL) and a high frequency of uremic complications in the every-other-day treatment arm. The results of this study may have reflected less than adequate therapy in the everyother-day treatment arm rather than an actual benefit of intensive therapy 14] . In order to avoid this issue, the delivered dose of hemodialysis in the present study will be intensively monitored and the prescription adjusted to ensure delivery of an adequate dose of therapy [27] .
In none of these studies were subjects permitted to transfer between modalities of treatment in response to changes in hemodynamic status, as commonly occurs in clinical practice, leading to restricted subject eligibility in some studies [7] and limited generalizability. In contrast, the ArN Stidy was designed with the expectation that subjects' hemodynamic status will change over the course of the study, necessitatinig conversion between modalities of therapy. This use of integrated manageiment strategies combining intermittent hemodialysis and CVVHDF or SLED, yet maintaining separation of intensity of therapy for each modality between strategies represents a unique innovation in the design of the study. While this design will make the results of the study more immediately generalizable to clinical practice, the combination of multiple modalities of KRT within each treatment arm introduced several issues that needed to be explicitly addressed in the study's design.
Comparability of dose of RRT between modalities
The first issue was the comparability of dose between modalities of RRT. Although several mathematical models has been developed to correlate the dose of RRT given on different schedules, none of these models has been validated in clinical practice [28] [29] [30] . As a result, the doses of continuous and intermittent therapy selected for the conventional treatment arm were based on an assessment of current clinical practice [9] , rather than on theoretical assessment of equivalence of dose. In the intensive treatment arm, the dosing of intermittent hemodialysis and SLED was established by doubling the frequency of treatment while the dose of CVVHDF was increased slightly less than twofold, as published data do not suggest further improvement in ouItcome with doses of CRRT beyond 35 mL/kg/hr [8] .
Integration of RRT modalities within treatment arms A second issue was the potential for confounding that could result if the patterns of switching between modalities differed between treatment arms. Although prior studies have not demonstrated differences in survival between intermittent and continuous therapy [19, [31] [32] [33] protocol-driven treatmnient strategies: an "experimental" arm with a lower tidal volume (6 mL/kg) and a "control" arm with a higher tidal volume (12 mL/kg), which the investigators believed corresponded to traditional recommendations for the management of mechanical ventilation. Two years after publication of the study results, the use of the protocol-driven higher tidal volume treatment arm as the control group was criticized as not representative of the best practice standards prevailing at the time of the trial [35] . The authors of this critique stated that this "study design may have resulted in substantial numbers of control subjects receiving inferior treatment" and contended that a nonprotocol-driven control group representing "what is believed by participating physicians to be the best current care" ("wild-type" therapy) shotuld have been included to provide generalizable results and to safeguard patient safety [35] . Furthermore, they suggested that the same design issues were present in an ongoing ARDS Network study evaluating the use of hemodynamic monitoring and fluid management strategies. Prompted by these criticisms, OHRP initiated an investigation of the two ARDS Network studies and, at the request of OHRI, NHLBI suspended the FACT-ITrial.
In its opinion, issued in a letter dated 3 July 2003, OHRP did not directly comment on the appropriateness of the design of the two trials, deferring to the near uLnanimous opinion of a panel of outside consultants that the risks to subjects participating in the trials "were minimized and reasonable" [10] . However, OHRP faulted the institutional review boards (lRBs) for their oversight of the studies, stating that they had failed to obtain sufficient information required to assess the risks to subjects 1O1]. Specifically, OHRIP stated that: "the IRBs should have received information adequate to assess the risks and potential benefits of each of the interventions for each arm of the... trial relative to concurrent routine clinical practice outside of the research context" [10] .
The design of the ATN Study has many similarities to these two ARDS Network trials. All three studies compare protocol-driven treatment strategies of titrated therapies; there is no clear consensus regarding best practice or precise knowledge of current practice patterns for the therapies being evaluated; and none of the trials was designed with a "wild-type" treatment arm as a control group.
Following the release of the OHRP findings, we considered mnultiple strategies to address these issues. The addition of a "wild-type" treatment arm was considered but was not feasible due to budgetary constraints. In addition, the scientific validity of a "wild-type" treatment arm was felt to be questionable given the likelihood of drift in treatment practice over time due to a Hawthorne effect. As 
